CN102421894A - 用于促进局部缺血性和糖尿病性创面愈合的组合物、试剂盒和方法 - Google Patents

用于促进局部缺血性和糖尿病性创面愈合的组合物、试剂盒和方法 Download PDF

Info

Publication number
CN102421894A
CN102421894A CN201080019437XA CN201080019437A CN102421894A CN 102421894 A CN102421894 A CN 102421894A CN 201080019437X A CN201080019437X A CN 201080019437XA CN 201080019437 A CN201080019437 A CN 201080019437A CN 102421894 A CN102421894 A CN 102421894A
Authority
CN
China
Prior art keywords
wound
sdf
selectin
diabetic
compsn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201080019437XA
Other languages
English (en)
Chinese (zh)
Inventor
O·C·維拉斯奎茲
Z-J·刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Publication of CN102421894A publication Critical patent/CN102421894A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201080019437XA 2009-04-21 2010-04-09 用于促进局部缺血性和糖尿病性创面愈合的组合物、试剂盒和方法 Pending CN102421894A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17127109P 2009-04-21 2009-04-21
US61/171,271 2009-04-21
PCT/US2010/030471 WO2010123699A2 (en) 2009-04-21 2010-04-09 Compositions, kits and methods for promoting ischemic and diabetic wound healing

Publications (1)

Publication Number Publication Date
CN102421894A true CN102421894A (zh) 2012-04-18

Family

ID=43011688

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080019437XA Pending CN102421894A (zh) 2009-04-21 2010-04-09 用于促进局部缺血性和糖尿病性创面愈合的组合物、试剂盒和方法

Country Status (6)

Country Link
US (1) US20120058086A1 (cg-RX-API-DMAC7.html)
EP (1) EP2421967A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012524781A (cg-RX-API-DMAC7.html)
KR (1) KR20120023633A (cg-RX-API-DMAC7.html)
CN (1) CN102421894A (cg-RX-API-DMAC7.html)
WO (1) WO2010123699A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106581068A (zh) * 2016-11-08 2017-04-26 广州医科大学附属第三医院 一种可以快速恢复皮肤创面的生物膜及其制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014233266A1 (en) * 2013-03-15 2015-10-22 Juventas Therapeutics, Inc. The use of SDF-1 to mitigate scar formation
EP3237622B1 (en) 2014-12-23 2021-02-24 Ilya Pharma AB Methods for wound healing
US20180028108A1 (en) * 2015-03-18 2018-02-01 Bio1 Systems, Llc Digital wound assessment device and method
CN110769861A (zh) * 2017-05-02 2020-02-07 迈阿密大学 治疗缺血性组织的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008118370A2 (en) * 2007-03-22 2008-10-02 The Trustees Of The University Of Pennsylvania Hyperbaric treatment in wound healing

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244043A1 (en) * 2005-03-10 2007-10-18 Novavax, Inc. Recombinant E-selectin made in insect cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008118370A2 (en) * 2007-03-22 2008-10-02 The Trustees Of The University Of Pennsylvania Hyperbaric treatment in wound healing

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN ET AL: "Combination of VEGF165/Angiopoietin-1 gene and endothelial progenitor cells for therapeutic neovascularization", 《EUROPEAN JOURNAL OF PHARMACOLOGY》 *
IL-YOUNG OH ET AL: "Involvement of E-selectin in recruitment of endothelial progenitor cells and angiogenesis in ischemic muscle", 《BLOOD》 *
NISHIWAKI ET AL: "Endothelial E-Selectin Potentiates Neovascularization via Endothelial Progenitor Cell-Dependent and -Independent Mechanisms", 《ARTERIOSCLER THROMB VASC BIOL》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106581068A (zh) * 2016-11-08 2017-04-26 广州医科大学附属第三医院 一种可以快速恢复皮肤创面的生物膜及其制备方法

Also Published As

Publication number Publication date
KR20120023633A (ko) 2012-03-13
WO2010123699A3 (en) 2011-01-06
JP2012524781A (ja) 2012-10-18
EP2421967A4 (en) 2013-01-02
EP2421967A2 (en) 2012-02-29
US20120058086A1 (en) 2012-03-08
WO2010123699A2 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
US10550165B2 (en) Peptide for inducing regeneration of tissue and use thereof
CA2504019C (en) Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
US20040131601A1 (en) Injection of bone marrow-derived cells and medium for angiogenesis
WO2004056186A1 (en) Cell-based vegf delivery
Shi et al. MCT1-mediated endothelial cell lactate shuttle as a target for promoting axon regeneration after spinal cord injury
Li et al. Optogenetic vagal nerve stimulation attenuates heart failure by limiting the generation of monocyte-derived inflammatory CCRL2+ macrophages
Liu et al. Identification of E-selectin as a novel target for the regulation of post-natal neovascularization: implications for diabetic wound healing
US20120058086A1 (en) Compositions, kits, and methods for promoting ischemic and diabetic wound healing
JP7450244B2 (ja) 虚血組織を治療するための方法
US20260041732A1 (en) Use of apelin for the treatment of lymphedema
JP2022507693A (ja) 心不全の治療及び予防における使用のためのリラキシン受容体1
US20220280607A1 (en) Treatment of Heart Defects and Conditions in Pediatric Patients
US20060051334A1 (en) Injection of bone marrow-derived conditioned medium for angiogenesis
US20240238346A1 (en) Myocardial wound healing post ischemic injury
CN107982519A (zh) P311蛋白在制备预防和/或治疗创面血管新生障碍或不足的药物中的应用
Yang The Role of Macrophage in Cartilage Regeneration and Therapy Development
JP2006519873A (ja) 血管形成を促進するための腫瘍内皮マーカー1、9、および17の使用
Pacak Gene delivery strategies for the treatment of cardiac and skeletal muscle in murine models of muscular dystrophy
AU2008200822A1 (en) Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
HK1195101B (en) Peptide for inducing regeneration of tissue and use thereof
HK1195101A (en) Peptide for inducing regeneration of tissue and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20120418